INO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Inovio Pharmaceuticals, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

2026-02-22 15:33:22

Abstract generation in progress

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and its officers, alleging that the company made materially false and misleading statements about its business operations and prospects between October 2023 and December 2025. Inovio shareholders who suffered losses during this period have the opportunity to seek to be appointed as lead plaintiff by April 7, 2026. The lawsuit claims that Inovio misrepresented its CELLECTRA device manufacturing, the likelihood of submitting the INO-3107 BLA to the FDA by 2024, and the eligibility of INO-3107 for accelerated approval or priority review, thereby overstating its regulatory and commercial prospects.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.